Ilyang Pharm Cash Flow-to-Debt Ratio
Ilyang Pharm cash flow-to-debt ratio. Ilyang Pharm (007570) has a Cash Flow-to-Debt Ratio of 0.01x as of June 2025, meaning its operating cash flow of ₩2.26 Billion could theoretically repay 0% of its total liabilities (₩205.41 Billion) in one year. Check Ilyang Pharm (007570) total reinvestment rate to assess the company's total reinvestment commitment from operating cash flow.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Cash Flow-to-Debt Ratio of Ilyang Pharm (2003–2024)
Cash flow-to-debt ratio of Ilyang Pharm from 2003 to 2024. Historical debt coverage capacity for Ilyang Pharm across 13 annual periods. Check how high is Ilyang Pharm's earnings quality to evaluate the quality of earnings relative to operating cash generation.
Ilyang Pharm Cash Flow-to-Debt Ratio by Year (2003–2024)
Ilyang Pharm cash flow-to-debt ratio by year from 2003 to 2024. Year-by-year debt coverage analysis for Ilyang Pharm. For the full cash flow conversion analysis, see 007570 cash generation efficiency.
| Year | CF-to-Debt Ratio | Operating CF (KRW) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2024 | 0.03x | ₩5.61 Billion | ₩189.63 Billion | ▼ -64.4% |
| 2023 | 0.08x | ₩13.34 Billion | ₩160.25 Billion | ▼ -42.6% |
| 2022 | 0.15x | ₩29.94 Billion | ₩206.33 Billion | ▼ -51.8% |
| 2021 | 0.30x | ₩67.02 Billion | ₩222.51 Billion | ▲ +1.8% |
| 2020 | 0.30x | ₩57.48 Billion | ₩194.19 Billion | ▲ +75.6% |
| 2019 | 0.17x | ₩36.19 Billion | ₩214.72 Billion | ▲ +69.5% |
| 2018 | 0.10x | ₩22.12 Billion | ₩222.37 Billion | ▼ -25.3% |
| 2017 | 0.13x | ₩30.03 Billion | ₩225.39 Billion | ▲ +5.6% |
| 2016 | 0.13x | ₩26.98 Billion | ₩213.91 Billion | ▼ -30.9% |
| 2015 | 0.18x | ₩40.27 Billion | ₩220.62 Billion | ▲ +142.4% |
| 2014 | 0.08x | ₩18.63 Billion | ₩247.37 Billion | ▲ +632.0% |
| 2013 | -0.01x | ₩-3.04 Billion | ₩214.50 Billion | ▼ -112.8% |
| 2003 | 0.11x | ₩10.08 Billion | ₩91.16 Billion | — |